Business
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors
– Initial clinical data expected mid-2026 – SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the patients in the first cohort have been dosed in its Phase 1 trial evaluating STRO-004 in a range of Tissue Factor (TF) expressing solid tumors. STRO-004 is the Company’s TF-targeting exatecan ADC en
About this update from Sutro Biopharma, Inc.
[{"type":"image","alt":"Sutro Biopharma, Inc.","displaySize":"","headline":null,"caption":"Sutro Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":186,"height":55,"url":"https://media.zenfs.com/en/globenewswire.com/ca5877b05c127c1dc6a01374ae1f5ab8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rd31Oc6_ZbJywDRY5HheFA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ca5877b05c127c1dc6a01374ae1f5ab8","width":186,"height":55}},"lazy":false},{"type":"text","content":"– Initial clinical data expected mid-2026 –","length":43,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the patients in the first cohort have been dosed in its Phase 1 trial evaluating STRO-004 in a range of Tissue Factor (TF) expressing solid tumors. STRO-004 is the Company’s TF-targeting exatecan ADC engineered for best-in-class stability, potency, and tumor selectivity using Sutro’s proprietary cell-free platform.","length":570,"tagName":"p"},{"type":"text","content":"“Dosing the initial patients in this trial marks an important milestone in bringing forward new treatment options for patients with TF–expressing cancers—many of whom face limited therapy options and difficult prognoses. We’ve seen strong engagement from our clinical investigators, who recognize the potential of STRO-004 to address a pressing need in oncology—and we’re proud of the speed and precision with which our team brought the program into the clinic,” said Jane Chung, Chief Executive Officer of Sutro Biopharma. “STRO-004 is engineered to deliver potent, sustained anti-tumor activity and higher exposure compared to approved therapies, with the goal of reaching tumors that are resistant to standard approaches. Through this trial, we aim to generate early insights into safety and activity that will guide development in areas of urgent unmet need. We are deeply grateful to the patients and investigators participating in this study and look forward to sharing initial data in mid-2026.”","length":1002,"tagName":"p"},{"type":"text","content":"The Phase 1 open-label, multicenter trial is designed t...